CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05708950
Title field or adapter rule: {'original_value': 'A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:24.215058+00:00
Published At: 2026-10-05T00:00:00+00:00
Record Updated At: 2026-10-05
Source Retrieved At: 2026-10-31T22:17:54.613222+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

protocolSection.conditionsModule.conditions: ["Cancer", "Solid Tumor", "Melanoma", "Carcinoma", "Sarcoma", "Lung Cancer", "Prostate Cancer", "Breast Cancer", "Colo-rectal Cancer", "Uterine Cancer", "Pancreatic Cancer", "Gastric Cancer", "Esophageal Cancer", "Thyroid Cancer", "Ovarian Cancer", "Kidney Cancer", "Head and Neck Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-05", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT05708950"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Open-label Trial of KVA12123 [TBS-2025] Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

{'armGroupLabels': ['KVA12123 [TBS-2025] Monotherapy Dose Escalation'], 'description': 'Ascending KVA12123 doses given as monotherapy by intravenous administration every 2 weeks of each 6-week cycle.', 'name': 'KVA12123 - Dose Escalation', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KVA12123 [TBS-2025] Plus Pembrolizumab Dose Escalation'], 'description': 'Ascending KVA12123 doses given by intravenous administration every 2 weeks of each 6-week cycle in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.', 'name': 'KVA12123 Plus Pembrolizumab - Dose Escalation', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KVA12123 [TBS-2025] Monotherapy Dose Expansion'], 'description': 'KVA12123 administered at the RP2D by intravenous administration every 2 weeks of each 6 week cycle.', 'name': 'KVA12123 - Dose Expansion', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['KVA12123 Plus Pembrolizumab Dose Expansion'], 'description': 'KVA12123 administered at the RP2D by intravenous administration every 2 weeks in combination with a fixed dose of pembrolizumab administered once every 6 week cycle.', 'name': 'KVA12123 Plus Pembrolizumab - Dose Expansion', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.